Relay Therapeutics(RLAY.US)

Company Encyclopedia

Relay Therapeutics

RLAY.US

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It transforms the drug discovery process with a focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company’s lead product candidates include RLY-2608, a pan-mutant and isoform-selective phosphoinostide 3 kinase alpha, or PI3Ka, inhibitor that is in clinical development for the treatment of breast cancer, solid tumor, and vascular malformations; and aGal chaperone for Fabry diseases.

1.813 T

RLAY.USMarket value -Rank by Market Cap -/-

Financial Score

19/05/2026 Update

BiotechnologyIndustry

Industry Ranking89/386

Industry medianC

Industry averageC

Score Analysis

Peer Comparison

Criteria
Rating
Profit ScoreE
- ROE-40.01%E
- Profit Margin-2554.37%E
- Gross Margin-2252.10%E
Growth ScoreB
- Revenue YoY39.03%A
- Net Profit YoY18.20%B
- Total Assets YoY-12.48%E
- Net Assets YoY-10.94%D
Cash ScoreB
- Cash Flow Margin78.24%C
- OCF YoY39.03%A
Operating ScoreE
- Turnover0.01E
Debt ScoreA
- Gearing Ratio8.21%A

Valuation analysis

P/E

10Y

P/E

Industry Ranking

-/-

P/E
Price
High
Median
Low

P/B

10Y

P/B

Industry Ranking

-/-

P/B
Price
High
Median
Low

P/S

10Y

P/S

Industry Ranking

-/-

P/S
Price
High
Median
Low

Dividend Yield

10Y

Dividend Yield

Industry Ranking

-/-

Dividend Yield
Price
High
Median
Low

Institutional View & Shareholder

Analyst Ratings

Rating

Percentage

Price
--
Highest
--
Lowest
--

Shareholder

Ownership	%Owned	Share Chg	Report Date
SB Investment Advisers (UK) Limited	14.57%	No Change	31/12/2025
Commodore Capital LP	8.87%	No Change	31/03/2026
Casdin Capital, LLC	7.53%	1.42 M	31/03/2026
BlackRock, Inc.	6.77%	-253.20 K	31/03/2026
The Vanguard Group, Inc.	5.06%	No Change	31/12/2025
Bellevue Asset Management AG	4.07%	-550.12 K	31/03/2026
State Street Global Advisors, Inc.	3.25%	-192.57 K	31/03/2026
Nextech Invest Ltd.	2.88%	825.00 K	31/03/2026
TCG Crossover Management, LLC	2.23%	1.05 M	31/03/2026
FMR LLC	1.93%	3.53 M	31/03/2026

Relay Therapeutics(RLAY.US)

Financial Score

Valuation analysis

Institutional View & Shareholder

Analyst Ratings

Relay Therapeutics Reports Early Success For Investigational Drug In Rare Vascular Disorders

Relay Therapeutics shares are trading higher after the company announced initial clinical data from the Phase 2 ReInspire trial of zovegalisib in vascular anomalies signaling the advantage of PI3Kα mutant-selective inhibition.

This Biotech's Drug Just Wiped The Floor With Forecasts